nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydrocodeine—CYP2D6—Fingolimod—multiple sclerosis	0.202	0.261	CbGbCtD
Dihydrocodeine—CYP3A4—Fingolimod—multiple sclerosis	0.128	0.166	CbGbCtD
Dihydrocodeine—CYP3A4—Methylprednisolone—multiple sclerosis	0.0828	0.107	CbGbCtD
Dihydrocodeine—CYP3A4—Triamcinolone—multiple sclerosis	0.0627	0.081	CbGbCtD
Dihydrocodeine—CYP3A4—Mitoxantrone—multiple sclerosis	0.0604	0.078	CbGbCtD
Dihydrocodeine—CYP3A4—Betamethasone—multiple sclerosis	0.0538	0.0695	CbGbCtD
Dihydrocodeine—CYP3A4—Prednisolone—multiple sclerosis	0.0531	0.0686	CbGbCtD
Dihydrocodeine—CYP3A4—Prednisone—multiple sclerosis	0.0502	0.0648	CbGbCtD
Dihydrocodeine—CYP2D6—Dexamethasone—multiple sclerosis	0.0492	0.0636	CbGbCtD
Dihydrocodeine—CYP3A4—Dexamethasone—multiple sclerosis	0.0313	0.0404	CbGbCtD
Dihydrocodeine—Angiopathy—Fingolimod—multiple sclerosis	0.00309	0.0145	CcSEcCtD
Dihydrocodeine—Mediastinal disorder—Fingolimod—multiple sclerosis	0.00307	0.0144	CcSEcCtD
Dihydrocodeine—Mental disorder—Fingolimod—multiple sclerosis	0.00299	0.014	CcSEcCtD
Dihydrocodeine—Hepatic enzyme increased—Mitoxantrone—multiple sclerosis	0.00268	0.0125	CcSEcCtD
Dihydrocodeine—Unspecified disorder of skin and subcutaneous tissue—Fingolimod—multiple sclerosis	0.00251	0.0118	CcSEcCtD
Dihydrocodeine—Nervous system disorder—Fingolimod—multiple sclerosis	0.00238	0.0111	CcSEcCtD
Dihydrocodeine—Skin disorder—Fingolimod—multiple sclerosis	0.00235	0.011	CcSEcCtD
Dihydrocodeine—Hypotension—Fingolimod—multiple sclerosis	0.00226	0.0106	CcSEcCtD
Dihydrocodeine—Paraesthesia—Fingolimod—multiple sclerosis	0.00218	0.0102	CcSEcCtD
Dihydrocodeine—Dyspnoea—Fingolimod—multiple sclerosis	0.00216	0.0101	CcSEcCtD
Dihydrocodeine—Gastrointestinal disorder—Fingolimod—multiple sclerosis	0.00209	0.0098	CcSEcCtD
Dihydrocodeine—Hepatobiliary disease—Cladribine—multiple sclerosis	0.00204	0.00954	CcSEcCtD
Dihydrocodeine—Urinary tract disorder—Cladribine—multiple sclerosis	0.00191	0.00895	CcSEcCtD
Dihydrocodeine—Urethral disorder—Cladribine—multiple sclerosis	0.0019	0.00888	CcSEcCtD
Dihydrocodeine—Angiopathy—Cladribine—multiple sclerosis	0.00175	0.00822	CcSEcCtD
Dihydrocodeine—Immune system disorder—Cladribine—multiple sclerosis	0.00175	0.00818	CcSEcCtD
Dihydrocodeine—Mediastinal disorder—Cladribine—multiple sclerosis	0.00174	0.00816	CcSEcCtD
Dihydrocodeine—Pruritus—Fingolimod—multiple sclerosis	0.00171	0.00803	CcSEcCtD
Dihydrocodeine—Mental disorder—Cladribine—multiple sclerosis	0.00169	0.00794	CcSEcCtD
Dihydrocodeine—Diarrhoea—Fingolimod—multiple sclerosis	0.00166	0.00777	CcSEcCtD
Dihydrocodeine—Hepatobiliary disease—Azathioprine—multiple sclerosis	0.00166	0.00776	CcSEcCtD
Dihydrocodeine—Dizziness—Fingolimod—multiple sclerosis	0.0016	0.00751	CcSEcCtD
Dihydrocodeine—Headache—Fingolimod—multiple sclerosis	0.00152	0.00711	CcSEcCtD
Dihydrocodeine—Affect lability—Prednisolone—multiple sclerosis	0.00148	0.00695	CcSEcCtD
Dihydrocodeine—Mood swings—Prednisolone—multiple sclerosis	0.00143	0.00669	CcSEcCtD
Dihydrocodeine—Unspecified disorder of skin and subcutaneous tissue—Cladribine—multiple sclerosis	0.00142	0.00667	CcSEcCtD
Dihydrocodeine—Immune system disorder—Azathioprine—multiple sclerosis	0.00142	0.00665	CcSEcCtD
Dihydrocodeine—Mediastinal disorder—Azathioprine—multiple sclerosis	0.00142	0.00664	CcSEcCtD
Dihydrocodeine—Confusional state—Cladribine—multiple sclerosis	0.00138	0.00649	CcSEcCtD
Dihydrocodeine—Affect lability—Triamcinolone—multiple sclerosis	0.00136	0.00639	CcSEcCtD
Dihydrocodeine—Affect lability—Methylprednisolone—multiple sclerosis	0.00136	0.00638	CcSEcCtD
Dihydrocodeine—Nervous system disorder—Cladribine—multiple sclerosis	0.00135	0.00631	CcSEcCtD
Dihydrocodeine—Skin disorder—Cladribine—multiple sclerosis	0.00133	0.00625	CcSEcCtD
Dihydrocodeine—Hepatic enzyme increased—Methotrexate—multiple sclerosis	0.00133	0.00625	CcSEcCtD
Dihydrocodeine—Hyperhidrosis—Cladribine—multiple sclerosis	0.00133	0.00622	CcSEcCtD
Dihydrocodeine—Mood swings—Triamcinolone—multiple sclerosis	0.00131	0.00615	CcSEcCtD
Dihydrocodeine—Mood swings—Methylprednisolone—multiple sclerosis	0.00131	0.00614	CcSEcCtD
Dihydrocodeine—Hypotension—Cladribine—multiple sclerosis	0.00128	0.00601	CcSEcCtD
Dihydrocodeine—Affect lability—Dexamethasone—multiple sclerosis	0.00124	0.0058	CcSEcCtD
Dihydrocodeine—Affect lability—Betamethasone—multiple sclerosis	0.00124	0.0058	CcSEcCtD
Dihydrocodeine—Paraesthesia—Cladribine—multiple sclerosis	0.00123	0.00578	CcSEcCtD
Dihydrocodeine—Dyspnoea—Cladribine—multiple sclerosis	0.00122	0.00574	CcSEcCtD
Dihydrocodeine—Somnolence—Cladribine—multiple sclerosis	0.00122	0.00572	CcSEcCtD
Dihydrocodeine—Mood swings—Betamethasone—multiple sclerosis	0.00119	0.00558	CcSEcCtD
Dihydrocodeine—Mood swings—Dexamethasone—multiple sclerosis	0.00119	0.00558	CcSEcCtD
Dihydrocodeine—Gastrointestinal disorder—Cladribine—multiple sclerosis	0.00119	0.00556	CcSEcCtD
Dihydrocodeine—Constipation—Cladribine—multiple sclerosis	0.00117	0.0055	CcSEcCtD
Dihydrocodeine—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—multiple sclerosis	0.00116	0.00542	CcSEcCtD
Dihydrocodeine—Feeling abnormal—Cladribine—multiple sclerosis	0.00113	0.0053	CcSEcCtD
Dihydrocodeine—Gastrointestinal pain—Cladribine—multiple sclerosis	0.00112	0.00526	CcSEcCtD
Dihydrocodeine—Urticaria—Cladribine—multiple sclerosis	0.00109	0.00511	CcSEcCtD
Dihydrocodeine—Abdominal pain—Cladribine—multiple sclerosis	0.00109	0.00509	CcSEcCtD
Dihydrocodeine—Skin disorder—Azathioprine—multiple sclerosis	0.00108	0.00508	CcSEcCtD
Dihydrocodeine—Affect lability—Prednisone—multiple sclerosis	0.00108	0.00505	CcSEcCtD
Dihydrocodeine—Hypotension—Azathioprine—multiple sclerosis	0.00104	0.00489	CcSEcCtD
Dihydrocodeine—Mood swings—Prednisone—multiple sclerosis	0.00104	0.00486	CcSEcCtD
Dihydrocodeine—Pruritus—Cladribine—multiple sclerosis	0.000972	0.00455	CcSEcCtD
Dihydrocodeine—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.000964	0.00452	CcSEcCtD
Dihydrocodeine—Convulsion—Mitoxantrone—multiple sclerosis	0.000958	0.00449	CcSEcCtD
Dihydrocodeine—Hallucination—Methylprednisolone—multiple sclerosis	0.000952	0.00446	CcSEcCtD
Dihydrocodeine—Diarrhoea—Cladribine—multiple sclerosis	0.00094	0.0044	CcSEcCtD
Dihydrocodeine—Feeling abnormal—Azathioprine—multiple sclerosis	0.00092	0.00431	CcSEcCtD
Dihydrocodeine—Gastrointestinal pain—Azathioprine—multiple sclerosis	0.000913	0.00428	CcSEcCtD
Dihydrocodeine—Confusional state—Mitoxantrone—multiple sclerosis	0.00091	0.00427	CcSEcCtD
Dihydrocodeine—Dizziness—Cladribine—multiple sclerosis	0.000908	0.00426	CcSEcCtD
Dihydrocodeine—Abdominal pain—Azathioprine—multiple sclerosis	0.000883	0.00414	CcSEcCtD
Dihydrocodeine—Skin disorder—Mitoxantrone—multiple sclerosis	0.000877	0.00411	CcSEcCtD
Dihydrocodeine—Vomiting—Cladribine—multiple sclerosis	0.000873	0.00409	CcSEcCtD
Dihydrocodeine—Hyperhidrosis—Mitoxantrone—multiple sclerosis	0.000873	0.00409	CcSEcCtD
Dihydrocodeine—Angiopathy—Methylprednisolone—multiple sclerosis	0.000868	0.00407	CcSEcCtD
Dihydrocodeine—Mood swings—Methotrexate—multiple sclerosis	0.000867	0.00406	CcSEcCtD
Dihydrocodeine—Rash—Cladribine—multiple sclerosis	0.000866	0.00406	CcSEcCtD
Dihydrocodeine—Hallucination—Betamethasone—multiple sclerosis	0.000865	0.00406	CcSEcCtD
Dihydrocodeine—Hallucination—Dexamethasone—multiple sclerosis	0.000865	0.00406	CcSEcCtD
Dihydrocodeine—Dermatitis—Cladribine—multiple sclerosis	0.000865	0.00405	CcSEcCtD
Dihydrocodeine—Immune system disorder—Methylprednisolone—multiple sclerosis	0.000864	0.00405	CcSEcCtD
Dihydrocodeine—Mediastinal disorder—Methylprednisolone—multiple sclerosis	0.000862	0.00404	CcSEcCtD
Dihydrocodeine—Headache—Cladribine—multiple sclerosis	0.00086	0.00403	CcSEcCtD
Dihydrocodeine—Hypotension—Mitoxantrone—multiple sclerosis	0.000844	0.00395	CcSEcCtD
Dihydrocodeine—Mental disorder—Methylprednisolone—multiple sclerosis	0.000838	0.00393	CcSEcCtD
Dihydrocodeine—Angioedema—Prednisolone—multiple sclerosis	0.000829	0.00389	CcSEcCtD
Dihydrocodeine—Nausea—Cladribine—multiple sclerosis	0.000816	0.00382	CcSEcCtD
Dihydrocodeine—Vertigo—Prednisolone—multiple sclerosis	0.000815	0.00382	CcSEcCtD
Dihydrocodeine—Paraesthesia—Mitoxantrone—multiple sclerosis	0.000811	0.0038	CcSEcCtD
Dihydrocodeine—Dyspnoea—Mitoxantrone—multiple sclerosis	0.000805	0.00377	CcSEcCtD
Dihydrocodeine—Somnolence—Mitoxantrone—multiple sclerosis	0.000803	0.00376	CcSEcCtD
Dihydrocodeine—Angiopathy—Betamethasone—multiple sclerosis	0.000789	0.0037	CcSEcCtD
Dihydrocodeine—Angiopathy—Dexamethasone—multiple sclerosis	0.000789	0.0037	CcSEcCtD
Dihydrocodeine—Convulsion—Prednisolone—multiple sclerosis	0.000786	0.00368	CcSEcCtD
Dihydrocodeine—Constipation—Mitoxantrone—multiple sclerosis	0.000772	0.00362	CcSEcCtD
Dihydrocodeine—Diarrhoea—Azathioprine—multiple sclerosis	0.000764	0.00358	CcSEcCtD
Dihydrocodeine—Angioedema—Triamcinolone—multiple sclerosis	0.000763	0.00357	CcSEcCtD
Dihydrocodeine—Angioedema—Methylprednisolone—multiple sclerosis	0.000761	0.00357	CcSEcCtD
Dihydrocodeine—Hallucination—Prednisone—multiple sclerosis	0.000754	0.00353	CcSEcCtD
Dihydrocodeine—Vertigo—Triamcinolone—multiple sclerosis	0.00075	0.00351	CcSEcCtD
Dihydrocodeine—Vertigo—Methylprednisolone—multiple sclerosis	0.000748	0.00351	CcSEcCtD
Dihydrocodeine—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.000744	0.00349	CcSEcCtD
Dihydrocodeine—Dizziness—Azathioprine—multiple sclerosis	0.000738	0.00346	CcSEcCtD
Dihydrocodeine—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000738	0.00346	CcSEcCtD
Dihydrocodeine—Convulsion—Triamcinolone—multiple sclerosis	0.000723	0.00339	CcSEcCtD
Dihydrocodeine—Convulsion—Methylprednisolone—multiple sclerosis	0.000721	0.00338	CcSEcCtD
Dihydrocodeine—Urticaria—Mitoxantrone—multiple sclerosis	0.000717	0.00336	CcSEcCtD
Dihydrocodeine—Hyperhidrosis—Prednisolone—multiple sclerosis	0.000716	0.00335	CcSEcCtD
Dihydrocodeine—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000714	0.00334	CcSEcCtD
Dihydrocodeine—Vomiting—Azathioprine—multiple sclerosis	0.00071	0.00333	CcSEcCtD
Dihydrocodeine—Rash—Azathioprine—multiple sclerosis	0.000704	0.0033	CcSEcCtD
Dihydrocodeine—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000704	0.0033	CcSEcCtD
Dihydrocodeine—Dermatitis—Azathioprine—multiple sclerosis	0.000703	0.0033	CcSEcCtD
Dihydrocodeine—Headache—Azathioprine—multiple sclerosis	0.0007	0.00328	CcSEcCtD
Dihydrocodeine—Dry mouth—Triamcinolone—multiple sclerosis	0.000695	0.00326	CcSEcCtD
Dihydrocodeine—Angioedema—Dexamethasone—multiple sclerosis	0.000692	0.00324	CcSEcCtD
Dihydrocodeine—Angioedema—Betamethasone—multiple sclerosis	0.000692	0.00324	CcSEcCtD
Dihydrocodeine—Angiopathy—Prednisone—multiple sclerosis	0.000687	0.00322	CcSEcCtD
Dihydrocodeine—Confusional state—Methylprednisolone—multiple sclerosis	0.000685	0.00321	CcSEcCtD
Dihydrocodeine—Immune system disorder—Prednisone—multiple sclerosis	0.000684	0.00321	CcSEcCtD
Dihydrocodeine—Vertigo—Betamethasone—multiple sclerosis	0.00068	0.00319	CcSEcCtD
Dihydrocodeine—Vertigo—Dexamethasone—multiple sclerosis	0.00068	0.00319	CcSEcCtD
Dihydrocodeine—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.000667	0.00313	CcSEcCtD
Dihydrocodeine—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000666	0.00312	CcSEcCtD
Dihydrocodeine—Paraesthesia—Prednisolone—multiple sclerosis	0.000665	0.00312	CcSEcCtD
Dihydrocodeine—Mental disorder—Prednisone—multiple sclerosis	0.000664	0.00311	CcSEcCtD
Dihydrocodeine—Nausea—Azathioprine—multiple sclerosis	0.000663	0.00311	CcSEcCtD
Dihydrocodeine—Skin disorder—Methylprednisolone—multiple sclerosis	0.00066	0.00309	CcSEcCtD
Dihydrocodeine—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000658	0.00309	CcSEcCtD
Dihydrocodeine—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000657	0.00308	CcSEcCtD
Dihydrocodeine—Convulsion—Betamethasone—multiple sclerosis	0.000656	0.00307	CcSEcCtD
Dihydrocodeine—Convulsion—Dexamethasone—multiple sclerosis	0.000656	0.00307	CcSEcCtD
Dihydrocodeine—Hypotension—Methylprednisolone—multiple sclerosis	0.000635	0.00298	CcSEcCtD
Dihydrocodeine—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000625	0.00293	CcSEcCtD
Dihydrocodeine—Urethral disorder—Methotrexate—multiple sclerosis	0.000621	0.00291	CcSEcCtD
Dihydrocodeine—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000618	0.00289	CcSEcCtD
Dihydrocodeine—Paraesthesia—Triamcinolone—multiple sclerosis	0.000612	0.00287	CcSEcCtD
Dihydrocodeine—Feeling abnormal—Prednisolone—multiple sclerosis	0.00061	0.00286	CcSEcCtD
Dihydrocodeine—Paraesthesia—Methylprednisolone—multiple sclerosis	0.00061	0.00286	CcSEcCtD
Dihydrocodeine—Dyspnoea—Triamcinolone—multiple sclerosis	0.000607	0.00285	CcSEcCtD
Dihydrocodeine—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000606	0.00284	CcSEcCtD
Dihydrocodeine—Nervous system disorder—Betamethasone—multiple sclerosis	0.000606	0.00284	CcSEcCtD
Dihydrocodeine—Angioedema—Prednisone—multiple sclerosis	0.000603	0.00282	CcSEcCtD
Dihydrocodeine—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000597	0.0028	CcSEcCtD
Dihydrocodeine—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000597	0.0028	CcSEcCtD
Dihydrocodeine—Vertigo—Prednisone—multiple sclerosis	0.000592	0.00278	CcSEcCtD
Dihydrocodeine—Urticaria—Prednisolone—multiple sclerosis	0.000588	0.00276	CcSEcCtD
Dihydrocodeine—Hypotension—Betamethasone—multiple sclerosis	0.000577	0.00271	CcSEcCtD
Dihydrocodeine—Hypotension—Dexamethasone—multiple sclerosis	0.000577	0.00271	CcSEcCtD
Dihydrocodeine—Angiopathy—Methotrexate—multiple sclerosis	0.000574	0.00269	CcSEcCtD
Dihydrocodeine—Vomiting—Mitoxantrone—multiple sclerosis	0.000574	0.00269	CcSEcCtD
Dihydrocodeine—Immune system disorder—Methotrexate—multiple sclerosis	0.000572	0.00268	CcSEcCtD
Dihydrocodeine—Convulsion—Prednisone—multiple sclerosis	0.000571	0.00268	CcSEcCtD
Dihydrocodeine—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000571	0.00267	CcSEcCtD
Dihydrocodeine—Rash—Mitoxantrone—multiple sclerosis	0.000569	0.00267	CcSEcCtD
Dihydrocodeine—Dermatitis—Mitoxantrone—multiple sclerosis	0.000569	0.00266	CcSEcCtD
Dihydrocodeine—Headache—Mitoxantrone—multiple sclerosis	0.000566	0.00265	CcSEcCtD
Dihydrocodeine—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000561	0.00263	CcSEcCtD
Dihydrocodeine—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.00056	0.00262	CcSEcCtD
Dihydrocodeine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000558	0.00261	CcSEcCtD
Dihydrocodeine—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000556	0.0026	CcSEcCtD
Dihydrocodeine—Paraesthesia—Betamethasone—multiple sclerosis	0.000555	0.0026	CcSEcCtD
Dihydrocodeine—Paraesthesia—Dexamethasone—multiple sclerosis	0.000555	0.0026	CcSEcCtD
Dihydrocodeine—Mental disorder—Methotrexate—multiple sclerosis	0.000555	0.0026	CcSEcCtD
Dihydrocodeine—Urticaria—Triamcinolone—multiple sclerosis	0.000541	0.00254	CcSEcCtD
Dihydrocodeine—Urticaria—Methylprednisolone—multiple sclerosis	0.00054	0.00253	CcSEcCtD
Dihydrocodeine—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000537	0.00252	CcSEcCtD
Dihydrocodeine—Nausea—Mitoxantrone—multiple sclerosis	0.000536	0.00251	CcSEcCtD
Dihydrocodeine—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000534	0.0025	CcSEcCtD
Dihydrocodeine—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000534	0.0025	CcSEcCtD
Dihydrocodeine—Nervous system disorder—Prednisone—multiple sclerosis	0.000528	0.00247	CcSEcCtD
Dihydrocodeine—Skin disorder—Prednisone—multiple sclerosis	0.000523	0.00245	CcSEcCtD
Dihydrocodeine—Hyperhidrosis—Prednisone—multiple sclerosis	0.00052	0.00244	CcSEcCtD
Dihydrocodeine—Feeling abnormal—Betamethasone—multiple sclerosis	0.000509	0.00239	CcSEcCtD
Dihydrocodeine—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000509	0.00239	CcSEcCtD
Dihydrocodeine—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000505	0.00237	CcSEcCtD
Dihydrocodeine—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000505	0.00237	CcSEcCtD
Dihydrocodeine—Vertigo—Methotrexate—multiple sclerosis	0.000495	0.00232	CcSEcCtD
Dihydrocodeine—Urticaria—Betamethasone—multiple sclerosis	0.000491	0.0023	CcSEcCtD
Dihydrocodeine—Urticaria—Dexamethasone—multiple sclerosis	0.000491	0.0023	CcSEcCtD
Dihydrocodeine—Dizziness—Prednisolone—multiple sclerosis	0.00049	0.00229	CcSEcCtD
Dihydrocodeine—Abdominal pain—Dexamethasone—multiple sclerosis	0.000489	0.00229	CcSEcCtD
Dihydrocodeine—Abdominal pain—Betamethasone—multiple sclerosis	0.000489	0.00229	CcSEcCtD
Dihydrocodeine—Paraesthesia—Prednisone—multiple sclerosis	0.000483	0.00226	CcSEcCtD
Dihydrocodeine—Pruritus—Triamcinolone—multiple sclerosis	0.000482	0.00226	CcSEcCtD
Dihydrocodeine—Pruritus—Methylprednisolone—multiple sclerosis	0.000481	0.00225	CcSEcCtD
Dihydrocodeine—Convulsion—Methotrexate—multiple sclerosis	0.000478	0.00224	CcSEcCtD
Dihydrocodeine—Rash—Prednisolone—multiple sclerosis	0.000467	0.00219	CcSEcCtD
Dihydrocodeine—Dermatitis—Prednisolone—multiple sclerosis	0.000467	0.00219	CcSEcCtD
Dihydrocodeine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000466	0.00218	CcSEcCtD
Dihydrocodeine—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000465	0.00218	CcSEcCtD
Dihydrocodeine—Headache—Prednisolone—multiple sclerosis	0.000464	0.00217	CcSEcCtD
Dihydrocodeine—Constipation—Prednisone—multiple sclerosis	0.00046	0.00216	CcSEcCtD
Dihydrocodeine—Confusional state—Methotrexate—multiple sclerosis	0.000454	0.00213	CcSEcCtD
Dihydrocodeine—Dizziness—Triamcinolone—multiple sclerosis	0.00045	0.00211	CcSEcCtD
Dihydrocodeine—Dizziness—Methylprednisolone—multiple sclerosis	0.000449	0.00211	CcSEcCtD
Dihydrocodeine—Feeling abnormal—Prednisone—multiple sclerosis	0.000444	0.00208	CcSEcCtD
Dihydrocodeine—Nervous system disorder—Methotrexate—multiple sclerosis	0.000441	0.00207	CcSEcCtD
Dihydrocodeine—Gastrointestinal pain—Prednisone—multiple sclerosis	0.00044	0.00206	CcSEcCtD
Dihydrocodeine—Nausea—Prednisolone—multiple sclerosis	0.00044	0.00206	CcSEcCtD
Dihydrocodeine—Pruritus—Dexamethasone—multiple sclerosis	0.000437	0.00205	CcSEcCtD
Dihydrocodeine—Pruritus—Betamethasone—multiple sclerosis	0.000437	0.00205	CcSEcCtD
Dihydrocodeine—Skin disorder—Methotrexate—multiple sclerosis	0.000437	0.00205	CcSEcCtD
Dihydrocodeine—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000435	0.00204	CcSEcCtD
Dihydrocodeine—Vomiting—Triamcinolone—multiple sclerosis	0.000433	0.00203	CcSEcCtD
Dihydrocodeine—Vomiting—Methylprednisolone—multiple sclerosis	0.000432	0.00202	CcSEcCtD
Dihydrocodeine—Rash—Triamcinolone—multiple sclerosis	0.000429	0.00201	CcSEcCtD
Dihydrocodeine—Dermatitis—Triamcinolone—multiple sclerosis	0.000429	0.00201	CcSEcCtD
Dihydrocodeine—Rash—Methylprednisolone—multiple sclerosis	0.000428	0.00201	CcSEcCtD
Dihydrocodeine—Dermatitis—Methylprednisolone—multiple sclerosis	0.000428	0.00201	CcSEcCtD
Dihydrocodeine—Urticaria—Prednisone—multiple sclerosis	0.000428	0.002	CcSEcCtD
Dihydrocodeine—Headache—Triamcinolone—multiple sclerosis	0.000427	0.002	CcSEcCtD
Dihydrocodeine—Headache—Methylprednisolone—multiple sclerosis	0.000426	0.00199	CcSEcCtD
Dihydrocodeine—Abdominal pain—Prednisone—multiple sclerosis	0.000425	0.00199	CcSEcCtD
Dihydrocodeine—Diarrhoea—Dexamethasone—multiple sclerosis	0.000423	0.00198	CcSEcCtD
Dihydrocodeine—Diarrhoea—Betamethasone—multiple sclerosis	0.000423	0.00198	CcSEcCtD
Dihydrocodeine—Hypotension—Methotrexate—multiple sclerosis	0.00042	0.00197	CcSEcCtD
Dihydrocodeine—Dizziness—Betamethasone—multiple sclerosis	0.000409	0.00191	CcSEcCtD
Dihydrocodeine—Dizziness—Dexamethasone—multiple sclerosis	0.000409	0.00191	CcSEcCtD
Dihydrocodeine—Nausea—Triamcinolone—multiple sclerosis	0.000405	0.0019	CcSEcCtD
Dihydrocodeine—Paraesthesia—Methotrexate—multiple sclerosis	0.000404	0.00189	CcSEcCtD
Dihydrocodeine—Nausea—Methylprednisolone—multiple sclerosis	0.000404	0.00189	CcSEcCtD
Dihydrocodeine—Dyspnoea—Methotrexate—multiple sclerosis	0.000401	0.00188	CcSEcCtD
Dihydrocodeine—Somnolence—Methotrexate—multiple sclerosis	0.0004	0.00187	CcSEcCtD
Dihydrocodeine—Vomiting—Dexamethasone—multiple sclerosis	0.000393	0.00184	CcSEcCtD
Dihydrocodeine—Vomiting—Betamethasone—multiple sclerosis	0.000393	0.00184	CcSEcCtD
Dihydrocodeine—OPRM1—IL4-mediated signaling events—IL4R—multiple sclerosis	0.000391	0.0315	CbGpPWpGaD
Dihydrocodeine—Rash—Dexamethasone—multiple sclerosis	0.00039	0.00183	CcSEcCtD
Dihydrocodeine—Rash—Betamethasone—multiple sclerosis	0.00039	0.00183	CcSEcCtD
Dihydrocodeine—Dermatitis—Betamethasone—multiple sclerosis	0.000389	0.00182	CcSEcCtD
Dihydrocodeine—Dermatitis—Dexamethasone—multiple sclerosis	0.000389	0.00182	CcSEcCtD
Dihydrocodeine—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000388	0.00182	CcSEcCtD
Dihydrocodeine—Headache—Betamethasone—multiple sclerosis	0.000387	0.00181	CcSEcCtD
Dihydrocodeine—Headache—Dexamethasone—multiple sclerosis	0.000387	0.00181	CcSEcCtD
Dihydrocodeine—Pruritus—Prednisone—multiple sclerosis	0.000381	0.00178	CcSEcCtD
Dihydrocodeine—Feeling abnormal—Methotrexate—multiple sclerosis	0.000371	0.00174	CcSEcCtD
Dihydrocodeine—Diarrhoea—Prednisone—multiple sclerosis	0.000368	0.00173	CcSEcCtD
Dihydrocodeine—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000368	0.00172	CcSEcCtD
Dihydrocodeine—Nausea—Betamethasone—multiple sclerosis	0.000367	0.00172	CcSEcCtD
Dihydrocodeine—Nausea—Dexamethasone—multiple sclerosis	0.000367	0.00172	CcSEcCtD
Dihydrocodeine—Urticaria—Methotrexate—multiple sclerosis	0.000357	0.00167	CcSEcCtD
Dihydrocodeine—Dizziness—Prednisone—multiple sclerosis	0.000356	0.00167	CcSEcCtD
Dihydrocodeine—Abdominal pain—Methotrexate—multiple sclerosis	0.000356	0.00167	CcSEcCtD
Dihydrocodeine—Vomiting—Prednisone—multiple sclerosis	0.000342	0.0016	CcSEcCtD
Dihydrocodeine—Rash—Prednisone—multiple sclerosis	0.000339	0.00159	CcSEcCtD
Dihydrocodeine—Dermatitis—Prednisone—multiple sclerosis	0.000339	0.00159	CcSEcCtD
Dihydrocodeine—Headache—Prednisone—multiple sclerosis	0.000337	0.00158	CcSEcCtD
Dihydrocodeine—Nausea—Prednisone—multiple sclerosis	0.00032	0.0015	CcSEcCtD
Dihydrocodeine—Pruritus—Methotrexate—multiple sclerosis	0.000318	0.00149	CcSEcCtD
Dihydrocodeine—Diarrhoea—Methotrexate—multiple sclerosis	0.000308	0.00144	CcSEcCtD
Dihydrocodeine—Dizziness—Methotrexate—multiple sclerosis	0.000297	0.00139	CcSEcCtD
Dihydrocodeine—OPRM1—Peptide GPCRs—CCR1—multiple sclerosis	0.000289	0.0232	CbGpPWpGaD
Dihydrocodeine—Vomiting—Methotrexate—multiple sclerosis	0.000286	0.00134	CcSEcCtD
Dihydrocodeine—Rash—Methotrexate—multiple sclerosis	0.000284	0.00133	CcSEcCtD
Dihydrocodeine—Dermatitis—Methotrexate—multiple sclerosis	0.000283	0.00133	CcSEcCtD
Dihydrocodeine—Headache—Methotrexate—multiple sclerosis	0.000282	0.00132	CcSEcCtD
Dihydrocodeine—Nausea—Methotrexate—multiple sclerosis	0.000267	0.00125	CcSEcCtD
Dihydrocodeine—OPRM1—TCR Signaling Pathway—CBLB—multiple sclerosis	0.000262	0.021	CbGpPWpGaD
Dihydrocodeine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000224	0.0181	CbGpPWpGaD
Dihydrocodeine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000224	0.0181	CbGpPWpGaD
Dihydrocodeine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000218	0.0175	CbGpPWpGaD
Dihydrocodeine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000218	0.0175	CbGpPWpGaD
Dihydrocodeine—CYP2D6—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000215	0.0173	CbGpPWpGaD
Dihydrocodeine—CYP2D6—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000215	0.0173	CbGpPWpGaD
Dihydrocodeine—OPRM1—G-protein activation—POMC—multiple sclerosis	0.00021	0.0169	CbGpPWpGaD
Dihydrocodeine—OPRM1—TCR Signaling Pathway—MALT1—multiple sclerosis	0.000205	0.0165	CbGpPWpGaD
Dihydrocodeine—CYP3A4—Irinotecan Pathway—BCHE—multiple sclerosis	0.000199	0.016	CbGpPWpGaD
Dihydrocodeine—OPRM1—Peptide GPCRs—CXCR3—multiple sclerosis	0.000191	0.0154	CbGpPWpGaD
Dihydrocodeine—OPRM1—Peptide GPCRs—CCR2—multiple sclerosis	0.000186	0.015	CbGpPWpGaD
Dihydrocodeine—CYP2D6—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000177	0.0142	CbGpPWpGaD
Dihydrocodeine—CYP2D6—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000177	0.0142	CbGpPWpGaD
Dihydrocodeine—OPRM1—TCR Signaling Pathway—IL17A—multiple sclerosis	0.000167	0.0134	CbGpPWpGaD
Dihydrocodeine—OPRM1—TCR Signaling Pathway—CD28—multiple sclerosis	0.000162	0.013	CbGpPWpGaD
Dihydrocodeine—OPRM1—G alpha (i) signalling events—S1PR1—multiple sclerosis	0.000155	0.0125	CbGpPWpGaD
Dihydrocodeine—OPRM1—IL4-mediated signaling events—IL10—multiple sclerosis	0.000153	0.0123	CbGpPWpGaD
Dihydrocodeine—OPRM1—IL4-mediated signaling events—CD40LG—multiple sclerosis	0.000153	0.0123	CbGpPWpGaD
Dihydrocodeine—OPRM1—IL4-mediated signaling events—IL4—multiple sclerosis	0.000149	0.012	CbGpPWpGaD
Dihydrocodeine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000142	0.0115	CbGpPWpGaD
Dihydrocodeine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000142	0.0115	CbGpPWpGaD
Dihydrocodeine—CYP3A4—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000141	0.0113	CbGpPWpGaD
Dihydrocodeine—CYP3A4—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000141	0.0113	CbGpPWpGaD
Dihydrocodeine—OPRM1—Peptide ligand-binding receptors—CCR1—multiple sclerosis	0.000136	0.0109	CbGpPWpGaD
Dihydrocodeine—OPRM1—Peptide ligand-binding receptors—CXCL13—multiple sclerosis	0.000136	0.0109	CbGpPWpGaD
Dihydrocodeine—OPRM1—G alpha (i) signalling events—RGS1—multiple sclerosis	0.000132	0.0106	CbGpPWpGaD
Dihydrocodeine—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.000128	0.0103	CbGpPWpGaD
Dihydrocodeine—OPRM1—Class A/1 (Rhodopsin-like receptors)—S1PR1—multiple sclerosis	0.000124	0.00995	CbGpPWpGaD
Dihydrocodeine—OPRM1—Peptide GPCRs—CCR5—multiple sclerosis	0.00012	0.00965	CbGpPWpGaD
Dihydrocodeine—OPRM1—GPCRs, Class A Rhodopsin-like—GPR65—multiple sclerosis	0.000116	0.00936	CbGpPWpGaD
Dihydrocodeine—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000115	0.00929	CbGpPWpGaD
Dihydrocodeine—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000115	0.00929	CbGpPWpGaD
Dihydrocodeine—OPRM1—G alpha (i) signalling events—CCR1—multiple sclerosis	0.000115	0.00922	CbGpPWpGaD
Dihydrocodeine—OPRM1—G alpha (i) signalling events—CXCL13—multiple sclerosis	0.000115	0.00922	CbGpPWpGaD
Dihydrocodeine—OPRM1—TCR Signaling Pathway—CD8A—multiple sclerosis	0.000112	0.00902	CbGpPWpGaD
Dihydrocodeine—OPRM1—GPCRs, Class A Rhodopsin-like—CCR1—multiple sclerosis	0.000106	0.00856	CbGpPWpGaD
Dihydrocodeine—OPRM1—TCR Signaling Pathway—CCR5—multiple sclerosis	0.000103	0.00825	CbGpPWpGaD
Dihydrocodeine—CYP2D6—Melatonin metabolism and effects—APOE—multiple sclerosis	0.000102	0.00821	CbGpPWpGaD
Dihydrocodeine—OPRM1—TCR Signaling Pathway—FAS—multiple sclerosis	0.000102	0.00818	CbGpPWpGaD
Dihydrocodeine—OPRM1—Class A/1 (Rhodopsin-like receptors)—GPR65—multiple sclerosis	9.96e-05	0.00802	CbGpPWpGaD
Dihydrocodeine—OPRM1—Peptide ligand-binding receptors—CCL3—multiple sclerosis	9.68e-05	0.00779	CbGpPWpGaD
Dihydrocodeine—OPRM1—GPCR ligand binding—S1PR1—multiple sclerosis	9.41e-05	0.00757	CbGpPWpGaD
Dihydrocodeine—CYP2D6—Biological oxidations—CYP27B1—multiple sclerosis	9.38e-05	0.00755	CbGpPWpGaD
Dihydrocodeine—CYP2D6—Biological oxidations—CYP24A1—multiple sclerosis	9.38e-05	0.00755	CbGpPWpGaD
Dihydrocodeine—CYP2D6—Metapathway biotransformation—CYP27B1—multiple sclerosis	9.25e-05	0.00745	CbGpPWpGaD
Dihydrocodeine—CYP2D6—Metapathway biotransformation—CYP24A1—multiple sclerosis	9.25e-05	0.00745	CbGpPWpGaD
Dihydrocodeine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR1—multiple sclerosis	9.11e-05	0.00733	CbGpPWpGaD
Dihydrocodeine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL13—multiple sclerosis	9.11e-05	0.00733	CbGpPWpGaD
Dihydrocodeine—OPRM1—Peptide ligand-binding receptors—CXCR3—multiple sclerosis	9e-05	0.00724	CbGpPWpGaD
Dihydrocodeine—OPRM1—Peptide ligand-binding receptors—CCR2—multiple sclerosis	8.75e-05	0.00704	CbGpPWpGaD
Dihydrocodeine—OPRM1—Opioid Signalling—POMC—multiple sclerosis	8.72e-05	0.00702	CbGpPWpGaD
Dihydrocodeine—OPRM1—G alpha (i) signalling events—CXCR3—multiple sclerosis	7.59e-05	0.00611	CbGpPWpGaD
Dihydrocodeine—OPRM1—GPCR ligand binding—GPR65—multiple sclerosis	7.59e-05	0.0061	CbGpPWpGaD
Dihydrocodeine—OPRM1—G alpha (i) signalling events—CCR2—multiple sclerosis	7.39e-05	0.00594	CbGpPWpGaD
Dihydrocodeine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	7.34e-05	0.00591	CbGpPWpGaD
Dihydrocodeine—OPRM1—GPCRs, Class A Rhodopsin-like—PTGER4—multiple sclerosis	7.3e-05	0.00587	CbGpPWpGaD
Dihydrocodeine—OPRM1—Peptide ligand-binding receptors—CXCL10—multiple sclerosis	7.27e-05	0.00585	CbGpPWpGaD
Dihydrocodeine—OPRM1—GPCRs, Class A Rhodopsin-like—CXCR3—multiple sclerosis	7.05e-05	0.00567	CbGpPWpGaD
Dihydrocodeine—OPRM1—GPCR ligand binding—CXCL13—multiple sclerosis	6.94e-05	0.00558	CbGpPWpGaD
Dihydrocodeine—OPRM1—GPCR ligand binding—CCR1—multiple sclerosis	6.94e-05	0.00558	CbGpPWpGaD
Dihydrocodeine—OPRM1—GPCRs, Class A Rhodopsin-like—CCR2—multiple sclerosis	6.85e-05	0.00551	CbGpPWpGaD
Dihydrocodeine—OPRM1—G alpha (i) signalling events—CNR1—multiple sclerosis	6.82e-05	0.00548	CbGpPWpGaD
Dihydrocodeine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL3—multiple sclerosis	6.49e-05	0.00522	CbGpPWpGaD
Dihydrocodeine—OPRM1—TCR Signaling Pathway—CD4—multiple sclerosis	6.44e-05	0.00518	CbGpPWpGaD
Dihydrocodeine—OPRM1—GPCRs, Class A Rhodopsin-like—CNR1—multiple sclerosis	6.33e-05	0.00509	CbGpPWpGaD
Dihydrocodeine—OPRM1—Peptide ligand-binding receptors—CCL5—multiple sclerosis	6.26e-05	0.00504	CbGpPWpGaD
Dihydrocodeine—OPRM1—Class A/1 (Rhodopsin-like receptors)—PTGER4—multiple sclerosis	6.25e-05	0.00503	CbGpPWpGaD
Dihydrocodeine—OPRM1—G alpha (i) signalling events—CXCL10—multiple sclerosis	6.14e-05	0.00494	CbGpPWpGaD
Dihydrocodeine—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	6.13e-05	0.00494	CbGpPWpGaD
Dihydrocodeine—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	6.13e-05	0.00494	CbGpPWpGaD
Dihydrocodeine—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	6.05e-05	0.00487	CbGpPWpGaD
Dihydrocodeine—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	6.05e-05	0.00487	CbGpPWpGaD
Dihydrocodeine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCR3—multiple sclerosis	6.04e-05	0.00486	CbGpPWpGaD
Dihydrocodeine—OPRM1—TCR Signaling Pathway—IL1B—multiple sclerosis	5.95e-05	0.00479	CbGpPWpGaD
Dihydrocodeine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR2—multiple sclerosis	5.87e-05	0.00472	CbGpPWpGaD
Dihydrocodeine—OPRM1—Peptide ligand-binding receptors—CCR5—multiple sclerosis	5.64e-05	0.00454	CbGpPWpGaD
Dihydrocodeine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CNR1—multiple sclerosis	5.42e-05	0.00436	CbGpPWpGaD
Dihydrocodeine—OPRM1—GPCR downstream signaling—S1PR1—multiple sclerosis	5.32e-05	0.00428	CbGpPWpGaD
Dihydrocodeine—OPRM1—G alpha (i) signalling events—CCL5—multiple sclerosis	5.28e-05	0.00425	CbGpPWpGaD
Dihydrocodeine—OPRM1—GPCR ligand binding—CCL3—multiple sclerosis	4.94e-05	0.00398	CbGpPWpGaD
Dihydrocodeine—OPRM1—Opioid Signalling—MAPK1—multiple sclerosis	4.93e-05	0.00397	CbGpPWpGaD
Dihydrocodeine—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	4.9e-05	0.00394	CbGpPWpGaD
Dihydrocodeine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	4.88e-05	0.00393	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling by GPCR—S1PR1—multiple sclerosis	4.83e-05	0.00389	CbGpPWpGaD
Dihydrocodeine—OPRM1—GPCR ligand binding—PTGER4—multiple sclerosis	4.76e-05	0.00383	CbGpPWpGaD
Dihydrocodeine—OPRM1—G alpha (i) signalling events—CCR5—multiple sclerosis	4.76e-05	0.00383	CbGpPWpGaD
Dihydrocodeine—OPRM1—TCR Signaling Pathway—TGFB1—multiple sclerosis	4.62e-05	0.00372	CbGpPWpGaD
Dihydrocodeine—OPRM1—GPCR ligand binding—CXCR3—multiple sclerosis	4.6e-05	0.0037	CbGpPWpGaD
Dihydrocodeine—OPRM1—TCR Signaling Pathway—MAPK1—multiple sclerosis	4.53e-05	0.00365	CbGpPWpGaD
Dihydrocodeine—OPRM1—GPCR downstream signaling—RGS1—multiple sclerosis	4.52e-05	0.00364	CbGpPWpGaD
Dihydrocodeine—OPRM1—GPCR ligand binding—CCR2—multiple sclerosis	4.47e-05	0.0036	CbGpPWpGaD
Dihydrocodeine—OPRM1—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	4.42e-05	0.00355	CbGpPWpGaD
Dihydrocodeine—OPRM1—Peptide ligand-binding receptors—POMC—multiple sclerosis	4.41e-05	0.00355	CbGpPWpGaD
Dihydrocodeine—OPRM1—Peptide ligand-binding receptors—CCL2—multiple sclerosis	4.31e-05	0.00347	CbGpPWpGaD
Dihydrocodeine—OPRM1—GPCR downstream signaling—GPR65—multiple sclerosis	4.29e-05	0.00345	CbGpPWpGaD
Dihydrocodeine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	4.2e-05	0.00338	CbGpPWpGaD
Dihydrocodeine—OPRM1—GPCR ligand binding—CNR1—multiple sclerosis	4.13e-05	0.00332	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling by GPCR—RGS1—multiple sclerosis	4.11e-05	0.0033	CbGpPWpGaD
Dihydrocodeine—CYP2D6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	3.97e-05	0.0032	CbGpPWpGaD
Dihydrocodeine—OPRM1—GPCR downstream signaling—CXCL13—multiple sclerosis	3.92e-05	0.00316	CbGpPWpGaD
Dihydrocodeine—OPRM1—GPCR downstream signaling—CCR1—multiple sclerosis	3.92e-05	0.00316	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling by GPCR—GPR65—multiple sclerosis	3.89e-05	0.00313	CbGpPWpGaD
Dihydrocodeine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	3.78e-05	0.00304	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling Pathways—LINGO1—multiple sclerosis	3.77e-05	0.00303	CbGpPWpGaD
Dihydrocodeine—OPRM1—G alpha (i) signalling events—POMC—multiple sclerosis	3.72e-05	0.00299	CbGpPWpGaD
Dihydrocodeine—OPRM1—GPCR ligand binding—CXCL10—multiple sclerosis	3.72e-05	0.00299	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling by GPCR—CCR1—multiple sclerosis	3.56e-05	0.00287	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling by GPCR—CXCL13—multiple sclerosis	3.56e-05	0.00287	CbGpPWpGaD
Dihydrocodeine—OPRM1—TCR Signaling Pathway—IL6—multiple sclerosis	3.48e-05	0.0028	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling Pathways—TAGAP—multiple sclerosis	3.26e-05	0.00263	CbGpPWpGaD
Dihydrocodeine—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	3.2e-05	0.00258	CbGpPWpGaD
Dihydrocodeine—OPRM1—GPCR ligand binding—CCL5—multiple sclerosis	3.2e-05	0.00257	CbGpPWpGaD
Dihydrocodeine—OPRM1—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	2.96e-05	0.00238	CbGpPWpGaD
Dihydrocodeine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	2.89e-05	0.00233	CbGpPWpGaD
Dihydrocodeine—OPRM1—GPCR ligand binding—CCR5—multiple sclerosis	2.88e-05	0.00232	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling Pathways—S1PR1—multiple sclerosis	2.85e-05	0.0023	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling Pathways—GPC5—multiple sclerosis	2.78e-05	0.00223	CbGpPWpGaD
Dihydrocodeine—OPRM1—GPCR downstream signaling—PTGER4—multiple sclerosis	2.69e-05	0.00216	CbGpPWpGaD
Dihydrocodeine—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	2.6e-05	0.00209	CbGpPWpGaD
Dihydrocodeine—OPRM1—GPCR downstream signaling—CXCR3—multiple sclerosis	2.6e-05	0.00209	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling by GPCR—CCL3—multiple sclerosis	2.54e-05	0.00204	CbGpPWpGaD
Dihydrocodeine—OPRM1—GPCR downstream signaling—CCR2—multiple sclerosis	2.53e-05	0.00203	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling by GPCR—PTGER4—multiple sclerosis	2.44e-05	0.00197	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling Pathways—RGS1—multiple sclerosis	2.43e-05	0.00195	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling by GPCR—CXCR3—multiple sclerosis	2.36e-05	0.0019	CbGpPWpGaD
Dihydrocodeine—OPRM1—GPCR downstream signaling—CNR1—multiple sclerosis	2.33e-05	0.00188	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling Pathways—GPR65—multiple sclerosis	2.3e-05	0.00185	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling by GPCR—CCR2—multiple sclerosis	2.29e-05	0.00185	CbGpPWpGaD
Dihydrocodeine—CYP2D6—Metabolism—SRM—multiple sclerosis	2.28e-05	0.00183	CbGpPWpGaD
Dihydrocodeine—OPRM1—GPCR ligand binding—POMC—multiple sclerosis	2.25e-05	0.00181	CbGpPWpGaD
Dihydrocodeine—OPRM1—GPCR ligand binding—CCL2—multiple sclerosis	2.2e-05	0.00177	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling by GPCR—CNR1—multiple sclerosis	2.12e-05	0.0017	CbGpPWpGaD
Dihydrocodeine—CYP2D6—Biological oxidations—POMC—multiple sclerosis	2.11e-05	0.0017	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling Pathways—CXCL13—multiple sclerosis	2.1e-05	0.00169	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling Pathways—CCR1—multiple sclerosis	2.1e-05	0.00169	CbGpPWpGaD
Dihydrocodeine—OPRM1—GPCR downstream signaling—CXCL10—multiple sclerosis	2.1e-05	0.00169	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling by GPCR—CXCL10—multiple sclerosis	1.91e-05	0.00153	CbGpPWpGaD
Dihydrocodeine—OPRM1—GPCR downstream signaling—CCL5—multiple sclerosis	1.81e-05	0.00145	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling by GPCR—CCL5—multiple sclerosis	1.64e-05	0.00132	CbGpPWpGaD
Dihydrocodeine—OPRM1—GPCR downstream signaling—CCR5—multiple sclerosis	1.63e-05	0.00131	CbGpPWpGaD
Dihydrocodeine—OPRM1—GPCR downstream signaling—IL2RA—multiple sclerosis	1.6e-05	0.00129	CbGpPWpGaD
Dihydrocodeine—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	1.6e-05	0.00129	CbGpPWpGaD
Dihydrocodeine—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	1.6e-05	0.00129	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling Pathways—CCL3—multiple sclerosis	1.5e-05	0.00121	CbGpPWpGaD
Dihydrocodeine—CYP3A4—Metabolism—SRM—multiple sclerosis	1.49e-05	0.0012	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling by GPCR—CCR5—multiple sclerosis	1.48e-05	0.00119	CbGpPWpGaD
Dihydrocodeine—CYP2D6—Metabolism—GPC5—multiple sclerosis	1.47e-05	0.00118	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling by GPCR—IL2RA—multiple sclerosis	1.46e-05	0.00117	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling Pathways—PTGER4—multiple sclerosis	1.44e-05	0.00116	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling Pathways—PGR—multiple sclerosis	1.42e-05	0.00114	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling Pathways—CXCR3—multiple sclerosis	1.39e-05	0.00112	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling Pathways—CD28—multiple sclerosis	1.38e-05	0.00111	CbGpPWpGaD
Dihydrocodeine—CYP3A4—Biological oxidations—POMC—multiple sclerosis	1.38e-05	0.00111	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling Pathways—CCR2—multiple sclerosis	1.36e-05	0.00109	CbGpPWpGaD
Dihydrocodeine—OPRM1—GPCR downstream signaling—POMC—multiple sclerosis	1.27e-05	0.00102	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling Pathways—CNR1—multiple sclerosis	1.25e-05	0.00101	CbGpPWpGaD
Dihydrocodeine—CYP2D6—Metabolism—RRM1—multiple sclerosis	1.22e-05	0.000978	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling by GPCR—POMC—multiple sclerosis	1.16e-05	0.00093	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling by GPCR—CCL2—multiple sclerosis	1.13e-05	0.00091	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling Pathways—CXCL10—multiple sclerosis	1.13e-05	0.000906	CbGpPWpGaD
Dihydrocodeine—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	1.05e-05	0.000844	CbGpPWpGaD
Dihydrocodeine—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	1.05e-05	0.000844	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling by GPCR—TYK2—multiple sclerosis	1.03e-05	0.000826	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling Pathways—CD86—multiple sclerosis	9.85e-06	0.000793	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling Pathways—CCL5—multiple sclerosis	9.7e-06	0.00078	CbGpPWpGaD
Dihydrocodeine—CYP3A4—Metabolism—GPC5—multiple sclerosis	9.6e-06	0.000772	CbGpPWpGaD
Dihydrocodeine—OPRM1—GPCR downstream signaling—IL2—multiple sclerosis	9.41e-06	0.000757	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling Pathways—SPP1—multiple sclerosis	8.98e-06	0.000723	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling Pathways—CCR5—multiple sclerosis	8.74e-06	0.000703	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling Pathways—IL2RA—multiple sclerosis	8.61e-06	0.000693	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling by GPCR—IL2—multiple sclerosis	8.54e-06	0.000687	CbGpPWpGaD
Dihydrocodeine—CYP3A4—Metabolism—RRM1—multiple sclerosis	7.95e-06	0.00064	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling Pathways—APOE—multiple sclerosis	7.95e-06	0.000639	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling Pathways—CD80—multiple sclerosis	7.19e-06	0.000578	CbGpPWpGaD
Dihydrocodeine—CYP2D6—Metabolism—BCHE—multiple sclerosis	6.98e-06	0.000562	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling Pathways—POMC—multiple sclerosis	6.83e-06	0.000549	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling Pathways—CCL2—multiple sclerosis	6.68e-06	0.000537	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling by GPCR—MAPK1—multiple sclerosis	6.54e-06	0.000526	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling Pathways—TYK2—multiple sclerosis	6.07e-06	0.000488	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling Pathways—IL2—multiple sclerosis	5.05e-06	0.000406	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling by GPCR—IL6—multiple sclerosis	5.02e-06	0.000404	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling Pathways—MMP9—multiple sclerosis	4.78e-06	0.000384	CbGpPWpGaD
Dihydrocodeine—CYP3A4—Metabolism—BCHE—multiple sclerosis	4.57e-06	0.000367	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling Pathways—STAT3—multiple sclerosis	4.25e-06	0.000342	CbGpPWpGaD
Dihydrocodeine—CYP2D6—Metabolism—APOE—multiple sclerosis	4.2e-06	0.000338	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling Pathways—MYC—multiple sclerosis	3.95e-06	0.000318	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling Pathways—TGFB1—multiple sclerosis	3.94e-06	0.000317	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling Pathways—MAPK1—multiple sclerosis	3.86e-06	0.000311	CbGpPWpGaD
Dihydrocodeine—CYP2D6—Metabolism—POMC—multiple sclerosis	3.61e-06	0.00029	CbGpPWpGaD
Dihydrocodeine—CYP2D6—Metabolism—ALB—multiple sclerosis	3.29e-06	0.000265	CbGpPWpGaD
Dihydrocodeine—OPRM1—Signaling Pathways—IL6—multiple sclerosis	2.97e-06	0.000239	CbGpPWpGaD
Dihydrocodeine—CYP3A4—Metabolism—APOE—multiple sclerosis	2.75e-06	0.000221	CbGpPWpGaD
Dihydrocodeine—CYP3A4—Metabolism—POMC—multiple sclerosis	2.36e-06	0.00019	CbGpPWpGaD
Dihydrocodeine—CYP3A4—Metabolism—ALB—multiple sclerosis	2.15e-06	0.000173	CbGpPWpGaD
